Ticker

No recent analyst price targets found for DGNOF.

Latest News for DGNOF

DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia

BROSSARD, Quebec, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that today, August 13, 2026, it has received Medical Device Marketing Authorization for the CARA System (CARA) from the Saudi Food and…

GlobeNewsWire • Aug 13, 2026
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists

BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a Health Canada Medical Device Licence authorizing the commercialization of its CARA System in…

GlobeNewsWire • Jul 27, 2026
DIAGNOS to Extend the Exercise Period of Stock Warrants

BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a "Warrant") from August 5, 2026 to June 5, 2027 (the "Amendment").

Globe News Wire • Jul 7, 2026
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform

BROSSARD, Quebec, June 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that Emerging Growth Research today released a new flash report on DIAGNOS, highlighting the Company's progress toward key regulatory…

GlobeNewsWire • Jun 5, 2026
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026

DIAGNOS invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.  BROSSARD, Quebec, June 03, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence…

GlobeNewsWire • Jun 3, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for DGNOF.

No Senate trades found for DGNOF.

No House trades found for DGNOF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top